NewLimit Stock

NewLimit is creating epigenetic reprogramming medications to cure diseases with significant unmet medical needs.

Sign up today and learn more about NewLimit Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About NewLimit Stock

NewLimit specializes in treating age-related diseases to extend the human health span. It works on developing epigenetic reprogramming medicines to treat diseases with large unmet needs.

Funding History

May 2023$40.0M


Co-Founder & Head of Machine Learning

Greg Johnson

Co-founder & Head of Research

Jacob Kimmel


Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: